It’s not uncommon for biomedical institutes as well as their funding partners to announce through press releases that a clinical trial they’re running has gotten off the ground and has started to enroll patients. For an outsider looking in, it may seem like they’re jumping the gun a bit. No patients have received the therapy. … Continue reading UCLA launches CIRM-funded clinical trial using engineered blood stem cells to fight hard-to-treat cancers
skin cancer
Helping patient’s fight back against deadliest form of skin cancer
Caladrius Biosciences has been funded by CIRM to conduct a Phase 3 clinical trial to treat the most severe form of skin cancer: metastatic melanoma. Metastatic melanoma is a disease with no effective treatment, only around 15 percent of people with it survive five years, and every year it claims an estimated 10,000 lives in … Continue reading Helping patient’s fight back against deadliest form of skin cancer
One man’s story points to hope against a deadly skin cancer
One of the great privileges and pleasures of working at the stem cell agency is the chance to meet and work with some remarkable people, such as my colleagues here at CIRM and the researchers we support. But for me the most humbling, and by far the most rewarding experience, is having a chance to … Continue reading One man’s story points to hope against a deadly skin cancer
Two for 2.0 and Two for us
It began as an ambitious idea; yesterday it became a reality when the CIRM Board approved two projects under CIRM 2.0, one of them a Phase 3 clinical trial for a deadly form of skin cancer. Just to recap, CIRM 2.0 was introduced by Dr. C. Randal Mills when he took over as President and … Continue reading Two for 2.0 and Two for us
The Stem Cellar 